# 摘要

| Ref | Title | Summary |
| --- | --- | --- |
| [^1] | [Technological Shocks and Algorithmic Decision Aids in Credence Goods Markets](https://arxiv.org/abs/2401.17929) | 该论文研究了在信任商品市场中，技术冲击和算法决策辅助如何帮助消费者获得更好的诊断和治疗，以提高市场效率和消费者福利。 |
| [^2] | [A necessary and sufficient condition for the existence of chaotic price dynamics in an exchange economy.](http://arxiv.org/abs/2309.09176) | 该论文研究了一个标准的交换经济模型，给出了在Walras-Samuelson价格调整过程中存在混沌价格动态的必要和充分条件，并应用了最近的研究结果进行了拓扑混沌存在性的分析。 |
| [^3] | [Motives for Delegating Financial Decisions.](http://arxiv.org/abs/2309.03419) | 为了解为什么投资者会委托金融决策给专家，作者进行了一项实验，结果发现，投资者委托的动机包括责任转嫁、决策成本和追求过去表现，而没有发现委托使风险更加可接受的动机。 |
| [^4] | [Social Media Emotions and IPO Returns.](http://arxiv.org/abs/2306.12602) | 本文研究了社交媒体表达的情感如何影响初次公开发行（IPO）股票的错价。社交媒体上分享的大量信息和观点可以引发炒作，导致投资者非理性买卖决策，从而在短期内高估股票，但经常在长期内得到修正。发现投资者热情高涨的IPO拥有更高的回报率，但这种热情可能是错放的，需要更长的时间才能实现可持续的成长。 |
| [^5] | [Valuing Pharmaceutical Drug Innovations.](http://arxiv.org/abs/2212.07384) | 通过市场价值和研发成本，估计了制药药品创新的平均价值。成功药品的平均价值为 16.2 亿美元，临床试验前阶段的平均价值为 6430 万美元，成本为 5850 万美元。 |

# 详细

[^1]: 技术冲击和算法决策辅助在信任商品市场中的应用

    Technological Shocks and Algorithmic Decision Aids in Credence Goods Markets

    [https://arxiv.org/abs/2401.17929](https://arxiv.org/abs/2401.17929)

    该论文研究了在信任商品市场中，技术冲击和算法决策辅助如何帮助消费者获得更好的诊断和治疗，以提高市场效率和消费者福利。

    

    在信任商品市场（如医疗保健或维修服务）中，消费者依赖具有更多信息的专家来进行准确的诊断和治疗。然而，专家在诊断能力方面存在限制，这损害了市场效率和消费者福利。技术突破可以替代或补充专家判断能力，有潜力缓解消费者受虐待的情况。本文研究了当技能分布和消费者的信息不对称时，竞争性专家如何采用新型诊断技术。我们区分了增加专家能力的新技术和辅助判断的算法决策辅助工具，在不影响专家个人诊断精度的同时提供辅助判断。我们表明，高能力专家可能会因为与低能力专家差异化而放弃决策辅助工具，从而逃避汇集均衡。在线实验的结果支持我们的假设，显示了这一情况。

    In credence goods markets such as health care or repair services, consumers rely on experts with superior information to adequately diagnose and treat them. Experts, however, are constrained in their diagnostic abilities, which hurts market efficiency and consumer welfare. Technological breakthroughs that substitute or complement expert judgments have the potential to alleviate consumer mistreatment. This article studies how competitive experts adopt novel diagnostic technologies when skills are heterogeneously distributed and obfuscated to consumers. We differentiate between novel technologies that increase expert abilities, and algorithmic decision aids that complement expert judgments, but do not affect an expert's personal diagnostic precision. We show that high-ability experts may be incentivized to forego the decision aid in order to escape a pooling equilibrium by differentiating themselves from low-ability experts. Results from an online experiment support our hypothesis, showi
    
[^2]: 一个交换经济中混沌价格动态存在的必要和充分条件

    A necessary and sufficient condition for the existence of chaotic price dynamics in an exchange economy. (arXiv:2309.09176v1 [econ.GN])

    [http://arxiv.org/abs/2309.09176](http://arxiv.org/abs/2309.09176)

    该论文研究了一个标准的交换经济模型，给出了在Walras-Samuelson价格调整过程中存在混沌价格动态的必要和充分条件，并应用了最近的研究结果进行了拓扑混沌存在性的分析。

    

    在这个研究中，我们研究了一个标准的交换经济模型，其中包括Cobb-Douglas类型的消费者，并给出了Walras-Samuelson（tatonnement）价格调整过程中存在拓扑混沌的必要和充分条件。这是对Deng、Khan、Mitra（2022）最近的研究结果在一个单峰区间映射的拓扑混沌存在性进行的新应用。

    In this note, we study a standard exchange economy model with Cobb-Douglas type consumers and give a necessary and sufficient condition for the existence of a topological chaos in the Walras-Samuelson (tatonnement) price adjustment process. This is a new application of a recent result characterising the existence of a topological chaos for a unimodal interval map by Deng, Khan, Mitra (2022).
    
[^3]: 为什么投资者委托金融决策？实验研究四种可能动机

    Motives for Delegating Financial Decisions. (arXiv:2309.03419v1 [econ.GN])

    [http://arxiv.org/abs/2309.03419](http://arxiv.org/abs/2309.03419)

    为了解为什么投资者会委托金融决策给专家，作者进行了一项实验，结果发现，投资者委托的动机包括责任转嫁、决策成本和追求过去表现，而没有发现委托使风险更加可接受的动机。

    

    为了解为什么投资者会委托金融决策给专家，我们进行了一项实验，并探究了四种可能的动机。实验结果显示，甚至在轻松的选择任务中，有相当大比例的投资者倾向于委托决策，这表明责任转嫁动机起了重要的作用。对于更复杂的任务，更多的投资者选择委托，这说明决策成本对某些投资者有影响。一些委托者选择了低质量的、收益较高的专家，这表明追求过去表现的动机也起到了一定作用。我们没有发现第四种可能动机：委托使风险更加可接受。

    Why do investors delegate financial decisions to supposed experts? We report a laboratory experiment designed to disentangle four possible motives. Almost 600 investors drawn from the Prolific subject pool choose whether or not to delegate a real-stakes choice among lotteries to a previous investor (an ``expert'') after seeing information on the performance of several available experts. We find that a surprisingly large fraction of investors delegate even trivial choice tasks, suggesting a major role for the blame shifting motive. A larger fraction of investors delegate our more complex tasks, suggesting that decision costs play a role for some investors. Some investors who delegate choose a low quality expert with high earnings, suggesting a role for chasing past performance. We find no evidence for a fourth possible motive, that delegation makes risk more acceptable.
    
[^4]: 社交媒体情感与IPO回报

    Social Media Emotions and IPO Returns. (arXiv:2306.12602v1 [q-fin.PR])

    [http://arxiv.org/abs/2306.12602](http://arxiv.org/abs/2306.12602)

    本文研究了社交媒体表达的情感如何影响初次公开发行（IPO）股票的错价。社交媒体上分享的大量信息和观点可以引发炒作，导致投资者非理性买卖决策，从而在短期内高估股票，但经常在长期内得到修正。发现投资者热情高涨的IPO拥有更高的回报率，但这种热情可能是错放的，需要更长的时间才能实现可持续的成长。

    

    本文研究了初次公开发行（IPO）回报的两个经验事实背后的潜在机制。通过分析在StockTwits和Twitter上表达的投资者情绪，发现这些社交媒体平台传达的情感可以帮助解释IPO股票的错价。社交媒体上分享的大量信息和观点可能会引发对某些股票的炒作，导致投资者的非理性买卖决策。这可能导致股票在短期内被高估，但常常会在长期内得到修正，因为股票的表现未能满足过高的期望。特别是，发现在上市前投资者热情高涨的IPO，其第一天回报率明显更高，为29.54％，而上市前投资者热情较低的IPO，其平均第一天回报率为16.91％。但是，这种初始热情可能是错放的，因为上市前投资者热情很高的IPO可能需要更长的时间才能实现可持续的成长。

    I examine potential mechanisms behind two stylized facts of initial public offerings (IPOs) returns. By analyzing investor sentiment expressed on StockTwits and Twitter, I find that emotions conveyed through these social media platforms can help explain the mispricing of IPO stocks. The abundance of information and opinions shared on social media can generate hype around certain stocks, leading to investors' irrational buying and selling decisions. This can result in an overvaluation of the stock in the short term but often leads to a correction in the long term as the stock's performance fails to meet the inflated expectations. In particular, I find that IPOs with high levels of pre-IPO investor enthusiasm tend to have a significantly higher first-day return of 29.54%, compared to IPOs with lower levels of pre-IPO investor enthusiasm, which have an average first-day return of 16.91%. However, this initial enthusiasm may be misplaced, as IPOs with high pre-IPO investor enthusiasm demon
    
[^5]: 评估制药药品创新价值

    Valuing Pharmaceutical Drug Innovations. (arXiv:2212.07384v2 [econ.GN] UPDATED)

    [http://arxiv.org/abs/2212.07384](http://arxiv.org/abs/2212.07384)

    通过市场价值和研发成本，估计了制药药品创新的平均价值。成功药品的平均价值为 16.2 亿美元，临床试验前阶段的平均价值为 6430 万美元，成本为 5850 万美元。

    

    我们通过估计药品市场价值和研发成本来衡量制药药品创新的价值。我们依靠市场对药品研发公告的反应来确定价值和成本。利用公司公告数据和日收益率，我们估计成功药品的平均价值为16.2亿美元。平均而言，发现阶段的药品评估为6430万美元，成本为5850万美元。三个临床试验阶段的平均成本分别为600万美元、3000万美元和4100万美元。我们还研究了将这些估计应用于支持药品研发的政策的可能性。

    We measure the $\textit{value of pharmaceutical drug innovations}$ by estimating the market values of drugs and their development costs. We rely on market responses to drug development announcements to identify the values and costs. Using data on announcements by firms and their daily stock returns, we estimate the average value of successful drugs at \$1.62 billion. At the discovery stage, on average, drugs are valued at \$64.3 million and cost \$58.5 million. The average costs of the three phases of clinical trials are \$0.6, \$30, and \$41 million, respectively. We also investigate applying these estimates to policies supporting drug development.
    

